.gif)
Teva Pharmaceutical Industries Ltd launch Zecuity, the first and only patch system in US designed to provide relief from migraine. Zecuity is a single-use, disposable patch system that delivers sumatriptan through the skin. Zecuity is a prescription medicine used for the acute treatment of migraine headaches with or without aura in adults.
Migraine is defined as recurring attacks of moderate to severe pain, and the International Headache Society’s diagnostic criteria for migraine include experiencing at least 5 attacks, lasting 4-72 hours if untreated, in addition to nausea and/or vomiting, or sensitivity to light or sound. Approximately 36 million people in the United States suffer from migraine. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. There is no absolute cure for migraine since its pathophysiology has yet to be fully understood.
In a clinical study, at two hours following application, significantly more patients using Zecuity versus a non-medicated patch system reported, as the study’s primary endpoint, no headache pain (18 per cent versus 9 per cent). The secondary endpoints of the study showed that, at two hours following application, significantly more patients reported no nausea (84 per cent versus 63 per cent), no sensitivity to sound (55 per cent versus 39 per cent), no sensitivity to light (51 per cent versus 36 per cent), or headache pain relief (53 per cent versus 29 per cent).
The most common side effects reported for Zecuity included pain, tingling, itching, warmth, discomfort or a change in the skin color at the application site of Zecuity.
Subscribe to PharmaTutor News Alerts by Email >>
